Arterys Cardio DL vs Tempus ECG-AF
AI Verdict
Choose Arterys Cardio DL if…
Choose Arterys Cardio DL if your primary need is advanced, rapid, and accurate quantitative analysis of cardiac MRI studies. This tool is ideal for cardiologists and radiologists requiring automated ventricle segmentations, 4D Flow post-processing for blood flow visualization, and quantitative delayed enhancement analysis to enhance diagnostic precision and reduce interpretation time.
View Arterys Cardio DL →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your goal is to proactively identify older patients at increased risk of developing new-onset atrial fibrillation within the next year using standard 12-lead ECGs. This solution is best suited for clinicians in cardiology, geriatrics, or internal medicine who need an AI-powered screening tool to support earlier identification and follow-up for AF risk in patients aged 65 or older without pre-existing AF.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Arterys Cardio DL | Tempus ECG-AF |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | Cloud-based (SaaS), integrates with existing PACS or EHR, web-based zero-footprint viewer (Mac, PC, tablet, phone). [4, 7, 9, 13, 27] | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Arterys Cardio DLArterys Cardio DL offers superior usability due to its cloud-based, vendor-agnostic platform, allowing access from anywhere and rapid analysis in seconds. Its editable automated contours provide flexibility and control to the user, enhancing the interactive experience.
Clinical Value
Tempus ECG-AFTempus ECG-AF offers a distinct clinical value by providing a predictive risk assessment for new-onset Atrial Fibrillation using a widely available and low-cost test (ECG). This proactive identification of high-risk patients can lead to earlier intervention and potentially prevent AF-related strokes, demonstrating a high impact on patient management and outcomes.
Pricing & Value
Tempus ECG-AFTempus ECG-AF clearly wins this dimension due to its transparent CMS reimbursement information, including specific CPT codes and a Medicare rate. This provides healthcare providers with a clear understanding of the financial viability and value proposition, which is crucial for adoption. Arterys Cardio DL's pricing information is not publicly available, making its value assessment more challenging.
Enterprise Readiness
Arterys Cardio DLBoth tools demonstrate strong enterprise readiness with FDA clearance, HIPAA compliance, and BAA availability. Arterys Cardio DL edges out slightly due to its cloud-based, vendor-agnostic platform that integrates into existing PACS/EHR workflows, offering broader compatibility and scalability across diverse enterprise environments.
Innovation
Tempus ECG-AFTempus ECG-AF demonstrates a slightly higher degree of innovation by applying AI to a widely available diagnostic test (ECG) for predictive risk assessment of new-onset Atrial Fibrillation. This shifts the paradigm from reactive diagnosis to proactive identification and intervention, representing a significant advancement in precision medicine.
Support & Docs
TieNeither the provided structured facts nor the web search results offer sufficient specific details regarding dedicated support channels, knowledge bases, or comprehensive documentation for either Arterys Cardio DL or Tempus ECG-AF to confidently declare a winner. While Tempus has general support contacts, specific support for ECG-AF is not clearly outlined.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Arterys Cardio DL | Tempus ECG-AF |
|---|---|---|
| Name | Arterys Cardio DL | Tempus ECG-AF |
| Company | ARTERYS | Tempus AI, Inc. |
| Description | FDA-cleared, cloud-based AI software that provides automated, editable ventricle segmentations for cardiac MRI analysis, drastically reducing interpretation time and enhancing diagnostic accuracy. | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. |
| Key Functionality | Automated ventricle segmentations for cardiac MRI; Deep learning algorithms for image analysis; 4D Flow post-processing; Quantitative Delayed Enhancement analysis. | AI-based algorithm for 12-lead ECG analysis; Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months; Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. |
| Specialties | Cardiology, Radiology | Cardiology, Geriatrics, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Arterys Cardio DL and Tempus ECG-AF.
Frequently Asked Questions
More Comparisons
More matchups featuring Arterys Cardio DL or Tempus ECG-AF
Backers
Who funded each tool's parent company.